# Igor Puzanov

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/igor-puzanov/

## Facts

| Field | Value |
| --- | --- |
| Citations | 56,684 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 92 |
| i10-index | 265 |
| Last Known Institution | Roswell Park Comprehensive Cancer Center |
| OpenAlex ID | https://openalex.org/A5049243227 |
| ORCID iD | https://orcid.org/0000-0002-9803-3497 |
| Works | 671 |

## Researcher papers

- [Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline](https://scholariq.org/papers/management-of-immune-related-adverse-events-in-patients-treated-with-immune/)
- [<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors](https://scholariq.org/papers/i-ras-i-mutations-in-cutaneous-squamous-cell-carcinomas-in-patients-treated-with/)
- [Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events](https://scholariq.org/papers/society-for-immunotherapy-of-cancer-sitc-clinical-practice-guideline-on-immune/)
- [Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy](https://scholariq.org/papers/melanoma-specific-mhc-ii-expression-represents-a-tumour-autonomous-phenotype-and/)
- [Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade](https://scholariq.org/papers/targeted-next-generation-sequencing-identifies-markers-of-response-to-pd-1/)
- [Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/merkel-cell-carcinoma-version-1-2018-nccn-clinical-practice-guidelines-in/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

## Researcher university

- [Roswell Park Comprehensive Cancer Center](https://scholariq.org/institutions/roswell-park-comprehensive-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.